Kevin Hrusovsky, Chairman of 908 Devices’ Board of Directors, is an American entrepreneur and healthcare visionary, who has dedicated his 30-year career to leading disruptive medical technology companies and shepherding a global movement to transform healthcare to Precision Health. He created Powering Precision Health foundation, an internationally renowned non-profit promoting a new era of medicine using biomarker innovation to achieve precision medicine. He is regarded as a pioneer, accelerating adoption and value creation for many “game changing” non-invasive early detection technologies for Oncology, Neuro-Degeneration and Cardiology which are transforming drug development and disease prevention. Mr. Hrusovsky previously held the roles of Executive Chairman, Chairman, and President and CEO at Quanterix Corporation (QTRX). Prior to Quanterix, he was CEO of Caliper Life Sciences (CALP – acquired by PKI), and Zymark Corporation (acquired by CALP), as well as, President of Life Sciences at PerkinElmer (PKI). He also held senior roles at FMC Corp and DuPont. His numerous board memberships include both public and privately held companies as well as educational, healthcare and technology non-profit organizations. He is the recipient of several distinguished awards including the 2019 EY Entrepreneur of the Year®, 2017 BBJ Innovation All-Star award for transforming the practices of medicine and health, the 2018 Lifetime Achievement Award for Leadership and the E.G. Bailey Entrepreneurship Award (2013), both from The Ohio State University. Mr. Hrusovsky serves on the board of directors of DA32 Life Science Tech Acquisition Corp. (DALS). He holds an M.B.A. from Ohio University and a B.S. in Mechanical Engineering from The Ohio State University and received an Honorary Doctorate from Framingham State University for contributions to life sciences.